{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05320588",
            "orgStudyIdInfo": {
                "id": "StarBridge-1"
            },
            "organization": {
                "fullName": "BiOneCure Therapeutics Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study in Patients With Advanced Cancers",
            "officialTitle": "A Phase 1/2 Study of BIO-106 As Monotherapy or In Combination With Pembrolizumab in Patients With Advanced Cancers (StarBridge-1)",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "a-study-in-patients-with-advanced-cancers"
        },
        "statusModule": {
            "statusVerifiedDate": "2022-07",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-03-25",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-04",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-04",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-04-02",
            "studyFirstSubmitQcDate": "2022-04-02",
            "studyFirstPostDateStruct": {
                "date": "2022-04-11",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2022-07-15",
            "lastUpdatePostDateStruct": {
                "date": "2022-07-19",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "BiOneCure Therapeutics Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "A first-in-human study using BIO-106 as a single agent and in combination with pembrolizumab in advanced cancers.",
            "detailedDescription": "This is an open-label, Phase 1/2, first-in-human (FIH), multiple ascending dose and dose-expansion study of BIO-106 administered as monotherapy and in combination with pembrolizumab. Phase 1 will define the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of BIO-106 that can be advanced to Phase 2. Phase 2 will define the preliminary efficacy of these regimens in the setting of advanced solid tumors with high unmet medical needs."
        },
        "conditionsModule": {
            "conditions": [
                "Advanced Cancer",
                "Advanced Solid Tumor",
                "Cancer",
                "Oncology"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "interventionModelDescription": "Multiple ascending dose and dose-expansion of BIO-106 administered as a single agent or in combination with pembrolizumab.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 332,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Single agent BIO-106",
                    "type": "EXPERIMENTAL",
                    "description": "Escalating doses followed by expansion targeting advanced cancers",
                    "interventionNames": [
                        "Drug: BIO-106"
                    ]
                },
                {
                    "label": "Combination BIO-106 plus pembrolizumab",
                    "type": "EXPERIMENTAL",
                    "description": "Escalating doses followed by expansion targeting advanced cancers",
                    "interventionNames": [
                        "Drug: BIO-106",
                        "Drug: Pembrolizumab"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "BIO-106",
                    "description": "BIO-106 is a novel antibody-drug conjugate (ADC) that targets the human trophoblast cell surface antigen 2 (Trop-2)",
                    "armGroupLabels": [
                        "Combination BIO-106 plus pembrolizumab",
                        "Single agent BIO-106"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Pembrolizumab",
                    "description": "Programmed death receptor-1 (PD 1)-blocking antibody",
                    "armGroupLabels": [
                        "Combination BIO-106 plus pembrolizumab"
                    ],
                    "otherNames": [
                        "Keytruda"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence of adverse events (AEs) and serious adverse events (SAEs) - (Phase 1)",
                    "description": "Escalation period",
                    "timeFrame": "1 year"
                },
                {
                    "measure": "Incidence and nature of dose-limiting toxicities (DLTs) - (Phase 1)",
                    "description": "Escalation period",
                    "timeFrame": "up to 21 days"
                },
                {
                    "measure": "Maximum tolerable dose (MTD) or a tolerated dose below MTD - (Phase 1)",
                    "description": "Escalation period",
                    "timeFrame": "1 year"
                },
                {
                    "measure": "Anti-tumor activity by objective response rate (ORR), disease control rate (DCR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS) - (Phase 2)",
                    "description": "Expansion period",
                    "timeFrame": "2 years"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Anti-tumor activity by objective response rate (ORR), disease control rate (DCR), duration of response (DOR), progression-free survival (PFS), and overall survival (OS) - (Phase 1)",
                    "description": "Escalation Period",
                    "timeFrame": "1 year"
                },
                {
                    "measure": "Incidence of adverse event of special interest (AESI) - (Phase 2)",
                    "description": "Expansion period",
                    "timeFrame": "2 years"
                },
                {
                    "measure": "Incidence of adverse events (AEs) and serious adverse events (SAEs) - (Phase 2)",
                    "description": "Expansion period",
                    "timeFrame": "2 years"
                },
                {
                    "measure": "PK (Cmax) of BIO-106 - (Phase 1/2)",
                    "description": "Escalation and expansion periods",
                    "timeFrame": "2 years"
                },
                {
                    "measure": "PK (AUC) of BIO-106 - (Phase 1/2)",
                    "description": "Escalation and expansion periods",
                    "timeFrame": "2 years"
                },
                {
                    "measure": "Incidence of anti-BIO-106 antibodies - (Phase 1/2)",
                    "description": "Escalation and expansion periods",
                    "timeFrame": "2 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Key Inclusion Criteria:\n\n* Patients histologically or cytologically documented, locally advanced or metastatic solid tumor.\n* Disease progression confirmed by imaging or other objective evidence after having received standard treatment; or patients with refractory solid tumors who cannot tolerate standard treatment or have contraindications to standard treatment.\n* Measurable disease as determined by RECIST v.1.1 or bone only disease.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n\nKey Exclusion Criteria:\n\n* History of severe hypersensitivity to any ingredient of the study drug(s), including pembrolizumab or other monoclonal antibody.\n\nImpaired cardiac function or history of clinically significant cardiac disease\n\n* Human Immunodeficiency virus (HIV) infection, active hepatitis B infection, or hepatitis C infection.\n* Active SARS-CoV-2 infection.\n* Untreated central nervous system (CNS), epidural tumor or metastasis, or brain metastasis.\n\nOther protocol defined inclusion/exclusion criteria may apply.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "BiOneCure Therapeutics Inc.",
                    "role": "CONTACT",
                    "phone": "(240) 912-9101",
                    "email": "Starbridge-1@bionecure.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "BiOneCure Clinical Development",
                    "affiliation": "BiOneCure Therapeutics Inc.",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "NEXT Oncology Austin",
                    "status": "RECRUITING",
                    "city": "Austin",
                    "state": "Texas",
                    "zip": "78758",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Cynthia DeLeon",
                            "role": "CONTACT",
                            "phone": "210-580-9521",
                            "email": "cdeleon@nextoncology.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 30.26715,
                        "lon": -97.74306
                    }
                },
                {
                    "facility": "University of Texas MD Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Funda Meric-Bernstam, MD",
                            "role": "CONTACT",
                            "phone": "832-483-8248",
                            "email": "fmeric@mdanderson.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                },
                {
                    "facility": "NEXT Oncology Virginia",
                    "status": "RECRUITING",
                    "city": "Fairfax",
                    "state": "Virginia",
                    "zip": "22031",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Malaika Komtangi",
                            "role": "CONTACT",
                            "phone": "210-580-9500",
                            "email": "mkomtangi@nextoncology.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.84622,
                        "lon": -77.30637
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "C000582435",
                    "term": "Pembrolizumab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000082082",
                    "term": "Immune Checkpoint Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M4225",
                    "name": "Antibodies",
                    "relevance": "LOW"
                },
                {
                    "id": "M349416",
                    "name": "Pembrolizumab",
                    "asFound": "Mg/m2",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10184",
                    "name": "Immunoglobulins",
                    "relevance": "LOW"
                },
                {
                    "id": "M21134",
                    "name": "Antibodies, Blocking",
                    "relevance": "LOW"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M2342",
                    "name": "Immune Checkpoint Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                }
            ]
        }
    },
    "hasResults": false
}